Sarcopenia is the loss of muscle mass and strength that happens with aging, affecting about 10% of adults over 60 and up to half of those over 80. It increases fall risk, slows recovery from illness, and can lead to loss of independence. Current treatment centers on resistance exercise and adequate protein intake, with no FDA-approved medications yet available.
What's actually going on in research
Trials are testing drugs that block myostatin and other muscle growth inhibitors, hormone therapies including selective androgen receptor modulators (SARMs), drugs that improve mitochondrial function in aging muscle, and supplements like urolithin A that may enhance muscle quality. Researchers are also studying electrical stimulation devices and combination approaches that pair exercise with medication.
Myostatin inhibitors
Blocking myostatin, a protein that limits muscle growth, may allow older adults to build and maintain muscle more effectively. Several antibody drugs targeting this pathway are in testing.
Selective androgen modulators
SARMs aim to provide the muscle-building effects of testosterone without affecting the prostate or other organs. Multiple compounds are in trials for age-related muscle loss.
Mitochondrial enhancers
Drugs that improve energy production in muscle cells may counter the mitochondrial decline that contributes to sarcopenia. Urolithin A and NAD+ boosters are being studied.
What to know before you search
Eligibility typically depends on age (usually 65 or older), measured muscle mass and strength below certain thresholds, and ability to participate in exercise testing.
What types of trials are currently open
- Drug trials — Testing medications that block muscle breakdown or enhance muscle growth, often combined with supervised exercise programs.
- Exercise intervention trials — Comparing different types of resistance training or evaluating exercise programs paired with nutritional supplements.
- Nutritional trials — Testing protein supplements, amino acid formulations, or compounds like urolithin A that may improve muscle quality.
- Device trials — Evaluating electrical muscle stimulation, vibration platforms, or other technologies designed to maintain muscle in people who can't exercise vigorously.
- Natural history studies — Following older adults to understand how sarcopenia progresses and what factors predict muscle loss or preservation.
Recently added Sarcopenia trials
Creatine Supplementation During GLP-1a Therapy
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.
The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer
Emerging data suggest consumption of dietary fiber before and during cancer treatment may improve prognosis for patients with head and neck cancer, in part via increased production of short chain fatty acids, systemic anti-inflammatory effects, and decreased risk of sarcopenia. Foods rich in dietary fiber are often low in calories and protein, thus are not typically targeted in current treatment paradigms that focus on countering the catabolic state associated with sarcopenia. This project entails an observational, mixed methods study to: observe dietary fiber intake in patients with head and neck cancer from time of diagnosis for six months; elucidate the relationship between dietary fiber intake, short chain fatty acids, inflammatory markers, and sarcopenia; and explore the feasibility of and patient perceptions regarding promoting dietary fiber as part of their treatment approaches.
Find Sarcopenia trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.